Buy & Sell Vertex Pharmaceuticals Incorporated (VRTX) – Vertex Pharmaceuticals Incorporated Price Today
Aura AI Summary
Key Stats
- $109.25BMarket Cap
- HealthSector
- -15.21%3M Drawdown
- $103.99BEnterprise Value
- -Dividend Yield
- 38% Buy | 62% SellTrading Activity
- 102 daysTypical Hold Time
Vertex Pharmaceuticals Incorporated (VRTX) is currently valued at a market capitalization of $109.25B, with an enterprise value of $103.99B. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $366.54 and a high of $499.17, highlighting its annual price range. Over the past three months, Vertex Pharmaceuticals Incorporated has recorded a drawdown of -15.21%, reflecting recent price volatility. On average, investors hold Vertex Pharmaceuticals Incorporated for approximately 102 days, indicating typical investor behavior on the platform.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Most Recent News
BlackRock's direct voting rights in Syensqo fall below 3%, triggering regulatory disclosure.
BlackRock Inc. has notified that its direct voting rights in Syensqo SA dropped below the 3% threshold as of May 11, 2026, holding 2.95% directly and 1.02% through equivalent financial instruments, totaling 3.97%. This regulatory disclosure follows B...
D-Wave exec sells $437K shares amid quantum computing stock surge on CHIPS Act funding news
D-Wave Quantum's Executive Vice President Sophie Ames sold $437,000 worth of shares as the company's stock surged following reports of potential CHIPS Act funding for quantum computing. The shares jumped 7.81% in after-hours trading, continuing a str...
Investor Gary Black doubts SpaceX IPO valuation near $1.75T, warns of overpricing and advises caution.
Investor Gary Black expressed skepticism about SpaceX's upcoming IPO, citing a valuation that could reach $1.75 trillion as too high. He noted that the expected price implies a valuation around 300 times EBITDA, leaving little room for upside and sug...
